What Causes Post-Inflammatory Hypopigmentation?
Discussion
Hypopigmentation can be worrisome for many families because of cosmesis and the worry that “something is wrong.” The normal natural changes in skin-tone over the year due to different light exposure and wide variations within individuals is not something that many people are aware of.
Post-inflammatory hypopigmentation is a common cause of hypopigmentation. Vitiligo is the most common cause of depigmentation.
Vitiligo is an acquired, depigmenting disorder with typical lesions appearing as milky white macules with distinct margins that are not scaly. Hair (including eyebrows and eyelashes) can be dep...
Source: PediatricEducation.org - November 12, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-cell Lymphoma
PRINCETON, N.J., Oct. 15, 2018 -- (Healthcare Sales & Marketing Network) -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where t... Biopharmaceuticals, Oncology Soligenix, hypericin, cutaneous T-cell lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 15, 2018 Category: Pharmaceuticals Source Type: news
Mogamulizumab Approved for Two Rare Types of Cutaneous T-cell Lymphoma
Mogamulizumab (Poteligeo) is indicated for relapsed or refractory mycosis fungoides or Sézary syndrome following at least one prior systemic therapy. (Source: CancerNetwork)
Source: CancerNetwork - September 11, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news
FDA Approves Poteligeo (mogamulizumab-kpkc) for Mycosis Fungoides and S ézary Syndrome
August 8, 2018 -- The U.S. Food and Drug Administration today approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or S ézary syndrome (SS) after... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 8, 2018 Category: Drugs & Pharmacology Source Type: news
FDA Approves New Drug for Cutaneous T-Cell Lymphomas FDA Approves New Drug for Cutaneous T-Cell Lymphomas
The FDA has granted approval for mogamulizumab-kpkc for adult patients with relapsed or refractory mycosis fungoides or S é zary syndrome.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 8, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
FDA approves treatment for two rare types of non-Hodgkin lymphoma
FDA approves new drug for the treatment of adults with relapsed or refractory mycosis fungoides or S ézary syndrome after at least one prior systemic therapy (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 8, 2018 Category: American Health Source Type: news
FDA approves treatment for two rare types of non-Hodgkin lymphoma
The U.S. Food and Drug Administration today approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. This approval provides a new treatment option for patients with MF and is the first FDA approval of a drug specifically for SS. (Source: World Pharma News)
Source: World Pharma News - August 8, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
Mycosis Fungoides and Sezary Syndrome
Mycosis Fungoides and S é zary Syndrome (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 16, 2018 Category: General Medicine Source Type: news
Proposed Remetinostat Phase III Design Results in Delay in Planned Start of Study
STOCKHOLM, June 18, 2018 -- (Healthcare Sales & Marketing Network) -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that the Board of Directors have decided to continue the discussions with the US Food and Drug Administration (FDA) to agree on the d... Biopharmaceuticals, Oncology Medivir, remetinostat, cutaneous T-cell lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 18, 2018 Category: Pharmaceuticals Source Type: news
New tool predicts deadly form of rare cancer
(Brigham and Women's Hospital) A tool to accurately determine which early-stage patients are at risk of dying from mycosis fungoides and which patients are likely to only require conventional therapy is desperately needed. Investigators from Brigham and Women's Hospital have found that next-generation, high-throughput sequencing of a specific gene (T-cell receptor beta or TCRB) is a stronger predictor of which early-stage patients will develop aggressive, progressive MF than any other established factor. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 9, 2018 Category: Cancer & Oncology Source Type: news
New Tool Predicts Deadly Form of Rare Cancer
Genetic sequencing from biopsy can accurately predict which early-stage Cutaneous T Cell Lymphoma (CTCL) patients have aggressive form of this disease (Source: BWH News)
Source: BWH News - May 9, 2018 Category: Hospital Management Source Type: news
Kim Debling shares photos of incurable cancer's disfiguring effects
Kim Debling, 34, from Basingstoke, Hampshire, is virtually unrecognisable after red lumps ravaged her face - caused by her stage four Cutaneous T-Cell lymphoma. (Source: the Mail online | Health)
Source: the Mail online | Health - May 3, 2018 Category: Consumer Health News Source Type: news
Mother-of-two, 34, with an incurable cancer releases shocking photos of its disfiguring effects
Kim Debling, 34, from Basingstoke, Hampshire, is virtually unrecognisable after red lumps ravaged her face - caused by her stage four Cutaneous T-Cell lymphoma. (Source: the Mail online | Health)
Source: the Mail online | Health - May 3, 2018 Category: Consumer Health News Source Type: news
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and S ézary Syndrome
A Guide for the Practicing OncologistThird Edition
CLICK HERE TO ACCESS THE WHITE PAPER (Source: CancerNetwork)
Source: CancerNetwork - February 20, 2018 Category: Cancer & Oncology Tags: Sponsored Resources Source Type: news
Mogamulizumab: Valuable New Option for Cutaneous Lymphoma Mogamulizumab: Valuable New Option for Cutaneous Lymphoma
An investigational monoclonal antibody directed against chemokine receptor 4 significantly improved progression-free survival in patients with cutaneous T-cell lymphoma.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
